Research output per year
Research output per year
Personal profile
Interests
Dr. Greene completed her PhD within the School of Pharmacy at Queen’s University Belfast, which focused on the therapeutic evaluation of a novel immunomodulatory nanoparticle in models of Acute Respiratory Distress Syndrome. Within her present role as a postdoctoral researcher, Dr. Greene has continued to apply her expertise in nanomedicine, particularly in the field of oncology. She is currently engaged in a US-Ireland R&D Partnership Programme that aims to develop more effective therapies for pancreatic cancer, by combining nanomedicines with agents that can overcome the drug delivery barriers posed by the tumour microenvironment.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Michelle Greene is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021
Greene, M. K., Smyth, P., English, A., McLaughlin, J., Bucholc, M., Bailie, J., McCarroll, J., McDonnell, M., Watt, A., Barnes, G., Lynch, M., Duffin, K., Duffy, G., Lewis, C., James, J., Stitt, A. W., Ford, T., O'Kane, M., Rai, T. S. & Bjourson, A. J. & 4 others, , 30 Jan 2024, In: Heliyon. 10, 2, 11 p., e24184.Research output: Contribution to journal › Article › peer-review
Open AccessFile65 Downloads (Pure) -
Comprehensive ocular and systemic safety evaluation of polysialic acid-decorated immune modulating therapeutic nanoparticles (PolySia-NPs) to support entry into first-in-human clinical trials
Krishnan, A., Callanan, D. G., Sendra, V. G., Lad, A., Christian, S., Earla, R., Khanehzar, A., Tolentino, A. J., Vailoces, V. A. S., Greene, M. K., Scott, C. J., Kunimoto, D. Y., Hassan, T. S., Genead, M. A. & Tolentino, M. J., 09 Apr 2024, In: Pharmaceuticals (Basel, Switzerland). 17, 4, 21 p., 481.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)16 Downloads (Pure) -
Development of CD33-targeted dual drug-loaded nanoparticles for the treatment of pediatric acute myeloid leukemia
Carvalho, A. M., Greene, M. K., Smyth, P., Mutch, A., McLaughlin, K. M., Cairns, L. V., Mills, K. I., McCloskey, K. D. & Scott, C. J., 05 Sept 2024, (Early online date) In: Biomacromolecules.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Downloads (Pure) -
Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors
Roy Chaudhuri, T., Lin, Q., Stachowiak, E. K., Rosario, S. R., Spernyak, J. A., Ma, W. W., Stachowiak, M. K., Greene, M. K., Quinn, G. P., McDade, S. S., Clynes, M., Scott, C. J. & Straubinger, R. M., 01 Apr 2024, In: Clinical Cancer Research. 30, 7, p. 1367-1381 15 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)46 Downloads (Pure) -
Nanoencapsulation of MDM2 inhibitor RG7388 and class-I HDAC inhibitor entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity
Abed, A., Greene, M. K., Alsa'd, A. A., Lees, A., Hindley, A., Longley, D. B., McDade, S. S. & Scott, C. J., 04 Mar 2024, In: Molecular Pharmaceutics. 21, 3, p. 1246–1255 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile15 Downloads (Pure)